Log In
BCIQ
Print this Print this
 

oxymorphone (COL-172)

  Manage Alerts
Collapse Summary General Information
Company Collegium Pharmaceutical Inc.
DescriptionOral sustained release opioid product utilizing DETERx technology
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentIND
Standard IndicationPain
Indication DetailsTreat moderate to severe pain; Treat moderate to severe pain in patients requiring continuous, around the clock opioid treatment for an extended period of time
Regulatory Designation U.S. - Fast Track (Treat moderate to severe pain in patients requiring continuous, around the clock opioid treatment for an extended period of time)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today